Key Highlights

● Fiscal 2026 Revenue was about $54.83 million, up 67.1%.

● The net loss was roughly $9.54 million.

● Cash and equivalents stood near $10.93 million at year-end.

● A July 14 framework with NOVA MEDIA targets an AI Digital Marketing system.

Haoxi Health Technology Limited (NASDAQ:HAO), a Beijing-based online marketing provider that serves health and wellness advertisers, enters the second half of November with a familiar tension in its story: sales have expanded quickly, yet the Business still loses money. The company has tried to address that gap partly through technology, signing a framework agreement this summer to develop an AI digital marketing system. For investors following small-cap Chinese Advertising names, the question is whether automation could eventually improve unit economics, or whether growth will continue to depend on outside capital.

Latest Company Context

According to financial data drawn from the company's SEC filings, Haoxi reported revenue of about $54.83 million for the fiscal year ended June 30, 2026, up 67.1% from the prior year, alongside a net loss of roughly $9.54 million. Cash and equivalents stood near $10.93 million at year-end. The Annual Report was filed around September 30, 2026. On July 14, the company announced a strategic cooperation framework with NOVA MEDIA aimed at building an AI digital marketing system. The year also brought significant capital-structure changes: a 1-for-128 reverse share split effective May 21 and a further 1-for-20 consolidation effective August 14, along with registered direct offerings of about $6.5 million in May and about $4 million in July.

Key Business and index Drivers

Haoxi's model centres on short-form video and news-feed advertising placed through major Chinese platforms such as Toutiao, Douyin and WeChat, with campaign planning, production, Placement and optimisation bundled for clients. That structure tends to carry thin margins, because a large share of client spending passes through to media platforms. An AI marketing system, if it moves beyond the framework stage, could potentially reduce production and optimisation costs or allow the company to price higher-value services.

However, the NOVA MEDIA agreement is a framework rather than a binding commercial contract, and no revenue contribution has been disclosed. Regulation of health-related advertising in China, competition from larger agencies and platform-owned ad tools, and the pace of client budgets in the wellness sector are additional variables that may shape results. Repeated share consolidations also signal ongoing pressure to maintain Nasdaq listing standards. Client concentration in the health sector could also amplify the effect of any single regulatory change.

What Investors Should Watch

Investors may watch for any 6-K filings describing concrete milestones under the NOVA MEDIA framework, such as a product launch, pilot clients or definitive agreements. Interim results for the six months ending December 31, 2026 would be the next full financial update; foreign private issuers typically report half-year figures in the following months, though no date has been confirmed. Gross Margin trends would be a useful gauge of whether technology Investment is changing the cost structure. Share count disclosures matter as well, given two reverse splits and two registered direct offerings within roughly three months. Any Nasdaq correspondence regarding bid price or Equity requirements would also be relevant, as would updates on how the company is deploying the cash raised this year. Disclosures on client retention and average spend per client would add further context.

Fast Revenue Growth, Persistent Losses

Haoxi's latest annual figures show a business that has scaled revenue quickly while remaining unprofitable, and its AI marketing initiative is still at an early, non-binding stage. Whether the technology push could narrow losses is not yet evident from disclosed results. For now, the company's trajectory may hinge on execution, margin discipline and its reliance on equity funding. Investors evaluating the stock might weigh the growth record against dilution history and the absence of confirmed revenue from the new initiative. Subsequent filings may clarify whether the AI effort becomes a measurable contributor.